Compare PHIN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHIN | STOK |
|---|---|---|
| Founded | 2023 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.0B |
| IPO Year | 2023 | 2019 |
| Metric | PHIN | STOK |
|---|---|---|
| Price | $64.07 | $33.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $66.33 | $36.10 |
| AVG Volume (30 Days) | 424.4K | ★ 702.1K |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 84.09 | 30.67 |
| EPS | ★ 3.24 | 0.85 |
| Revenue | N/A | ★ $36,555,000.00 |
| Revenue This Year | $6.60 | $428.68 |
| Revenue Next Year | $1.48 | N/A |
| P/E Ratio | ★ $19.48 | $39.05 |
| Revenue Growth | N/A | ★ 316.34 |
| 52 Week Low | $36.25 | $5.35 |
| 52 Week High | $81.00 | $40.22 |
| Indicator | PHIN | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 32.13 | 48.51 |
| Support Level | $51.15 | $31.60 |
| Resistance Level | $70.98 | $35.75 |
| Average True Range (ATR) | 2.24 | 2.35 |
| MACD | -1.28 | -0.28 |
| Stochastic Oscillator | 7.17 | 19.25 |
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.